Calliditas Therapeutics AB announced that it will hold an in-person and virtual R&D day on Thursday, May 30, 2024 at 3:00 PM CET.
STOCKHOLM, May 16, 2024 /PRNewswire/ -- Calliditas Therapeutics AB (NASDAQ: CALT) (NASDAQ Stockholm: CALTX) (“Calliditas”) today announced that it will hold an in-person and virtual R&D day on Thursday, May 30, 2024 at 3:00 PM CET (9:00 AM ET). The event will be held at Inderes Event Studio, Västra Trädgårdsgatan 19, Stockholm.
The event will feature Gareth J. Thomas, PhD (University Hospital Southampton) and Jonathan Barratt, PhD, FRCP (University of Leicester) with the following program:
- Supportive preclinical data and Phase 2 POC trial evaluating setanaxib, the Company’s lead candidate from its NOX platform, in patients with squamous cell carcinoma of the head and neck (SCCHN)
- The anti-fibrotic effects of Setanaxib in solid tumors and fibrotic diseases
- Review of upcoming additional clinical data from the NOX platform
- Support for mode of action of TARPEYO (Nefecon) in patients with primary IgA nephropathy (IgAN)
The event will include a discussion of positive clinical results and supportive pre-clinical and biomarker data recently announced for both programs, as well as an overview of the Company’s pipeline and expected future data readouts.
A live question and answer session will follow the formal presentations.
Registration information
You are required to register in advance for this event by clicking here.
Q&A information
If you would like to ask a question during the live Q&A, please submit your request to questions@lifesciadvisors.com
KOL Biographies
Gareth J. Thomas is Professor of Experimental Pathology at the University of Southampton, UK. As a clinical pathologist and tumor biologist, Gareth Thomas’s research is focused how fibroblasts affect cancer progression, characterizing the phenotypes and functions of different fibroblast subpopulations and investigating how fibroblasts interact with immune cells to suppress anti-tumor immunity. The research has a strong translational component aiming to develop new therapies that target fibroblasts to overcome immunotherapy resistance.
Jonathan Barratt, PhD, FRCP leads the Renal Research Group within the Col-lege of Life Sciences, University of Leicester. His research is focused on a bench to bedside approach to improving our understanding of the pathogenesis of IgA nephropathy a common global cause of kidney failure. Jonathan is the IgA nephropathy Rare Disease Group lead for the UK National Registry of Rare Kidney Diseases (RaDaR) and a member of the steering committee for the In-ternational IgA Nephropathy Network. He is Chief Investigator for a number of international randomized controlled Phase 2 and 3 clinical trials in IgA nephropa-thy and was a member of the FDA and American Society of Nephrology Kidney Health Initiative: Identifying Surrogate Endpoints for Clinical Trials in IgA Nephropathy Work group.
For further information, please contact:
Åsa Hillsten, Head of IR & Sustainability, Calliditas
Tel.: +46 76 403 35 43, Email: asa.hillsten@calliditas.com
The information was sent for publication, through the agency of the contact persons set out above, on May 16, 2024 at 16:30 p.m. CET.
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
| KOL Invite PR - ENG |
View original content:https://www.prnewswire.com/news-releases/in-person--virtual-rd-day-the-anti-fibrotic-effects-of-setanaxib-and-tarpeyos-mode-of-action-302147977.html
SOURCE Calliditas Therapeutics
Company Codes: Stockholm:CALTX, NASDAQ-NMS:CALT, Bloomberg:CALTX@SS, ISIN:SE0010441584, RICS:CALTX.ST
